오피오이드 사용 장애 시장 규모, 점유율, 동향 분석 보고서 : 약물별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Opioid Use Disorder Market Growth & Trends:

The global opioid use disorder market size is expected to reach USD 10.24 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 11.15% from 2025 to 2030. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

Opioid Use Disorder Market Report Highlights:

• Buprenorphine led the market and accounted for 59.58% of the global revenue in 2024 due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk.
• The injectable segment dominated the market and accounted for 59.26% of the global revenue in 2024. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse.
• Hospital pharmacies dominated the market with a market share of 47.90% in 2024 due to their integral role in managing complex and severe cases.
• North America opioid use disorder market accounted for 68.98% share in 2024 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary Distribution Channels
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Distribution Channels
• 1.9. List of Primary Distribution Channels
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug
  • 2.2.2. Route of Administration
  • 2.2.3. Distribution Channel
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Opioid Use Disorder Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising opioid epidemic
    • 3.2.1.2. Growing government initiatives to combat the crisis
    • 3.2.1.3. Growing awareness of opioid use disorder (OUD)
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Adverse effects associated to drug used for opioid treatment
    • 3.2.2.2. Complex reimbursement structure
• 3.3. Opioid Use Disorder Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis
• 3.5. Pipeline Analysis
• 3.6. Qualitative analysis about Behavioral Therapies

Chapter 4. Opioid Use Disorder Market Analysis, by Drug, 2018-2030 (USD Million)

• 4.1. Drug Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Opioid Use Disorder Market by Drug Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Buprenorphine
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Belbuca
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Suboxone
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Zubsolv
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Methadone
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Naltrexone
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Opioid Use Disorder Market Analysis, by Route of Administration, 2018-2030 (USD Million)

• 5.1. Opioid Use Disorder: Route of Administration Movement Analysis
• 5.2. Opioid Use Disorder Market Analysis, by Route of Administration Market (USD Million)
  • 5.2.1. Oral Administration
    • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 5.2.2. Injectable Administration
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 5.2.3. Others
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 6. Opioid Use Disorder Market Analysis, by Distribution Channel, 2018-2030 (USD Million)

• 6.1. Opioid Use Disorder: Distribution Channel Movement Analysis
• 6.2. Opioid Use Disorder Market Analysis, by Distribution Channel Market (USD Million)
  • 6.2.1. Hospital Pharmacies
    • 6.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 6.2.2. Retail Pharmacies
    • 6.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 6.2.3. Others
    • 6.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 7. Opioid Use Disorder Market: Regional Estimates and Trend Analysis by Drug, by Route of Administration, by Distribution Channel

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Indivior PLC
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Drug benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Teva Pharmaceutical Industries, Ltd.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Drug benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Pfizer, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Drug benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. BioDelivery Sciences International, Inc. (a part of Collegium Pharmaceutical, Inc.)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Drug benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Genentech, Inc. (Roche)
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Drug benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Alkermes.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Drug benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Orexo US Inc. (subsidiary of Orexo AB)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Drug benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Titan Pharmaceuticals, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Drug benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Omeros Corporation
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Drug benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Camurus AB
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Drug benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Hikma Pharmaceuticals PLC
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Drug benchmarking
    • 8.3.14.4. Strategic initiatives